ENVB Enveric Biosciences, Inc.
USHealthcareAs of 2026-07-02
Why ENVB matters now
Enveric Biosciences, Inc. (ENVB) is a US stock in Healthcare. The latest InvestLog snapshot shows $1.45 with -3.33% on the session and $865.7K in market capitalization; recent performance reads 1-month -39.34% and YTD -64.74%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-1.6M, and EPS of $-1.08. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -1047.8%.
The latest indexable market news headline is "Enveric Biosciences Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit" from Business Wire.
Additional event context on this page matters because analyst consensus is Buy with a median target of $—; recent insider activity includes Coveney Kevin Michael filing A-Award. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.38
P/S
0.00
EV/EBITDA
0.51
DCF Value
$12.39
FCF Yield
-1047.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-221.0%
ROA
-148.9%
ROIC
-162.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-1.6M | $-1.08 |
| Q4 2025 | $0.00 | $-2.2M | $-3.81 |
| FY 2025 | $0.00 | $-12.1M | $-36.24 |
| Q3 2025 | $0.00 | $-1.9M | $-10.81 |
Analyst Ratings
Consensus
Buy
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
US
Exchange
—
Beta
1.10
Enveric Biosciences, Inc. is a pharmaceutical firm focused on advancing diverse cannabinoid-based medications, primarily for use in cancer care. The company's robust product pipeline includes EV104, developed for treating osteoarthritis, and EVM-101 and EVM-201, which are intended to alleviate cancer-related distress. Furthermore, EVM-301 is under development for a mental health indication, alongside EV102, a cannabinoid cream formulated for topical skin application. Rounding out their portfolio is EV101, a novel combination therapy integrating cannabinoids with chemotherapy. This innovative company is based in Naples, Florida.